final program.qxd - Parallels Plesk Panel

PP 4.9
The significantly different profile on lipid metabolism and its correlates, caused by
efavirenz compared with Nevirapine
Roberto Manfredi, Leonardo Calza
Infectious Diseases, University of Bologna, Italy
Introduction
Altered metabolism represents an emerging feature of HIV-infected patients (p) treated
with HAART, but limited informations are avilable regarding the two non-nucleoside
reverse transcriptase inhibitor (NNRTI): respectively, efavirenz (E) and nevirapine (N).
Patients and Methods
Among over 1,000 p treated with HAART for over 12 months, the metabolic pattern of
NNRTI was assessed according to three different backgrounds. The first one included
antiretroviral-naïve p starting a NNRTI-based regimen;the second included a large
spectrum of p experienced with two to ten therapeutic lines (but remained still
NNRTI-naïve); the third group included p who added for the first time a NNRTI only on late
rescue therapies containing four drugs or more (and including protease inhibitors).
Results
Three hundred and 86 p treated with E were compared with 334 p taking N in our
prospective observational survey lasting 12 to 30 months, by a multivariate analysis of
serum lipid and glucose levels, and other metabolic abnormalities. Among the 213 p who
were naïve to antiretrovirals, an altered triglyceridemia was more common (p